West Pharmaceutical Services (WST) to Release Quarterly Earnings on Thursday

West Pharmaceutical Services (NYSE:WST) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, July 24th. Analysts expect West Pharmaceutical Services to post earnings of $1.51 per share and revenue of $725.11 million for the quarter. West Pharmaceutical Services has set its FY 2025 guidance at 6.150-6.350 EPS.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, April 24th. The medical instruments supplier reported $1.45 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.23. West Pharmaceutical Services had a return on equity of 18.23% and a net margin of 16.13%. The company had revenue of $698.00 million during the quarter, compared to analysts’ expectations of $685.24 million. During the same period in the prior year, the company earned $1.56 EPS. West Pharmaceutical Services’s revenue was up .4% compared to the same quarter last year. On average, analysts expect West Pharmaceutical Services to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

West Pharmaceutical Services Stock Up 1.6%

Shares of WST opened at $224.50 on Thursday. West Pharmaceutical Services has a 52 week low of $187.43 and a 52 week high of $352.33. The stock has a market capitalization of $16.13 billion, a price-to-earnings ratio of 35.24, a PEG ratio of 5.44 and a beta of 1.09. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.03 and a current ratio of 2.77. The stock has a fifty day moving average of $217.88 and a 200-day moving average of $243.92.

West Pharmaceutical Services Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 6th. Shareholders of record on Wednesday, July 30th will be issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 0.37%. The ex-dividend date of this dividend is Wednesday, July 30th. West Pharmaceutical Services’s payout ratio is 13.19%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Citigroup reissued a “buy” rating on shares of West Pharmaceutical Services in a report on Thursday, May 22nd. Stephens raised shares of West Pharmaceutical Services to a “strong-buy” rating in a report on Monday, April 21st. Finally, Barclays assumed coverage on shares of West Pharmaceutical Services in a report on Tuesday, June 24th. They set an “equal weight” rating and a $245.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $320.00.

Institutional Investors Weigh In On West Pharmaceutical Services

Institutional investors have recently modified their holdings of the company. Empowered Funds LLC boosted its stake in West Pharmaceutical Services by 16.1% during the first quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier’s stock worth $361,000 after acquiring an additional 224 shares in the last quarter. Intech Investment Management LLC boosted its stake in West Pharmaceutical Services by 27.7% during the first quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier’s stock worth $1,348,000 after acquiring an additional 1,307 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its stake in West Pharmaceutical Services by 14.1% during the first quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier’s stock worth $284,000 after acquiring an additional 157 shares in the last quarter. 93.90% of the stock is owned by institutional investors.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.